Nanomedicine for uterine leiomyoma therapy

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Background: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. Methods/Results: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and X-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 M. Conclusion: This novel approach represents a potential fertility-preserving alternative to hysterectomy.

Original languageEnglish (US)
Pages (from-to)161-175
Number of pages15
JournalTherapeutic Delivery
Issue number2
StatePublished - Feb 2013

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Nanomedicine for uterine leiomyoma therapy'. Together they form a unique fingerprint.

Cite this